Global Short Bowel Syndrome Market - 2025 -2033
Short Bowel Syndrome Market Size
In 2023, the global short bowel syndrome market was valued at US$ 1.39 Billion, and the market size reached US$ 1.64 Billion in 2024 and is expected to reach US$ 7.93 Billion by 2033, growing at a CAGR of 19.3% during the forecast period 2025-2033.
Short Bowel Syndrome Market Overview
The global short bowel syndrome (SBS) market is undergoing rapid evolution, driven by the growing incidence of gastrointestinal surgeries, particularly in neonates, along with increased adoption of advanced therapies such as GLP-2 analogs, including teduglutide. Key market drivers include rising prevalence of SBS due to conditions like Crohn’s disease and necrotizing enterocolitis, the clinical success of absorption-enhancing drugs that reduce reliance on parenteral nutrition, and improving access to care in emerging markets.
North America dominates the market due to high diagnosis rates, established reimbursement frameworks, and early drug approvals. Meanwhile, Asia-Pacific is the fastest-growing region, fueled by rising awareness, expanding pediatric surgical capabilities, and strategic entry by global pharmaceutical players.
Emerging opportunities lie in the development of biosimilars to reduce treatment costs, digital platforms for individualized nutrition management, and a robust pipeline of long-acting GLP-2 analogs and regenerative therapies that address long-term intestinal failure. These trends position the SBS market as a high-value niche with substantial room for targeted innovation and regional expansion.
Short Bowel Syndrome Market Dynamics: Drivers & Restraints
Drivers:
Rising prevalence of SBS & related GI disorders is significantly driving the short bowel syndrome market growth
The rising prevalence of short bowel syndrome (SBS), driven by increasing rates of gastrointestinal surgeries, Crohn’s disease, and necrotizing enterocolitis, especially among neonates and older adults, is a key growth driver for the SBS market. As more patients are diagnosed with SBS and require long-term nutritional and therapeutic support, demand for specialized treatments such as GLP-2 analogs and parenteral nutrition continues to rise.
This expanding patient population not only creates a larger commercial opportunity for pharmaceutical companies but also accelerates investment in drug development, diagnostic tools, and supportive care infrastructure, collectively propelling market growth.
Advancements in therapeutics are expected to boost the Short Bowel Syndrome market growth
Advancements in therapeutics are playing a pivotal role in driving growth in the Short Bowel Syndrome (SBS) market by offering more effective and convenient treatment options that reduce reliance on parenteral nutrition. A notable example is Apraglutide, a long-lasting GLP 2 analogue developed by Ironwood/VectivBio, which recently demonstrated statistically significant reductions in weekly parenteral support in a Phase III trial.
Another notable development is Glepaglutide from Zealand Pharma, an investigational GLP 2 analog in an autoinjector format, which earned FDA orphan drug designation and showed strong phase III results, though a Complete Response Letter in December 2024 prompted plans for an additional confirmatory trial. Collectively, such developments are fueling investment and adoption in the SBS market, creating sustained growth momentum.
Restraint:
The high cost of treatment and nutritional support are hampering the growth of the Short Bowel Syndrome market
The high cost of treatment and nutritional support is a significant barrier to the growth of the Short Bowel Syndrome (SBS) market, particularly in low- and middle-income regions. Managing SBS often requires lifelong dependence on parenteral nutrition (PN), specialized medical care, and advanced pharmacological therapies such as GLP 2 analogs (e.g., teduglutide).
For instance, teduglutide therapy can exceed $300,000 annually per patient in the U.S., while long-term PN can cost tens of thousands of dollars each year, excluding the additional burden of hospitalizations, catheter-related infections, and liver complications.
Opportunity:
Emergence of novel therapies is expected to create a lucrative opportunity for the growth of the short bowel syndrome market
Focusing on immuno-oncology and precision medicine is expected to create lucrative opportunities for the short bowel syndrome market by enabling the development of highly targeted, effective treatments tailored to individual patients. thymic tumors often present unique molecular and immune characteristics, making them suitable candidates for precision-based approaches. advances in genomic profiling, biomarker identification, and next-generation sequencing are allowing researchers to better understand the biology of short bowel syndrome, leading to the creation of personalized therapies that improve treatment response and reduce side effects.
Short Bowel Syndrome Market, Segment Analysis
The global short bowel syndrome market is segmented based on drug class, Route of Administration, distribution channel, and region.
The GLP-2 analogs from the drug class segment are expected to hold 31.6% of the market share in 2024 in the short bowel syndrome market
The GLP-2 analogs segment is expected to dominate the short bowel syndrome (SBS) drug market due to its targeted mechanism of action, proven clinical efficacy, and increasing regulatory approvals. GLP-2 (glucagon-like peptide-2) analogs enhance intestinal absorption by promoting mucosal growth and improving fluid and nutrient uptake, reducing the dependence on parenteral nutrition.
Teduglutide (marketed as Gattex in the U.S. and Revestive in Europe), the first GLP-2 analog approved by the FDA and EMA, has shown significant improvements in patients' nutritional autonomy and quality of life, driving strong adoption. Moreover, the segment is gaining momentum from a robust pipeline of next-generation GLP-2 analogs. For instance, Apraglutide by Ironwood Pharmaceuticals (formerly VectivBio) demonstrated positive Phase III results in 2024, showing a substantial reduction in weekly parenteral support volumes.
Similarly, Glepaglutide, developed by Zealand Pharma, is under regulatory review following Phase III trials, with additional studies planned after receiving a Complete Response Letter from the FDA in late 2024. These agents offer longer half-lives and more convenient dosing schedules, which are likely to further increase patient adherence and physician preference. As these advanced GLP-2 analogs enter the market, this drug class is well-positioned to remain the cornerstone of SBS pharmacological therapy.
Short Bowel Syndrome Market, Geographical Analysis
North America is expected to dominate the global short bowel syndrome market with a 40.3% share in 2024
North America is expected to dominate the global short bowel syndrome (SBS) market, largely due to its high disease burden, advanced healthcare infrastructure, and early adoption of innovative treatments. The region, particularly the United States, accounts for the majority of SBS cases globally. Byrne et al. estimated that around 10,000 to 20,000 patients in the United States receive home-based total parenteral nutrition (TPN) for short bowel syndrome (SBS). Patients are dependent on long-term home parenteral nutrition. The rising incidence of conditions leading to SBS alongside improved survival rates among preterm infants has expanded the patient population. Moreover, the region benefits from strong reimbursement frameworks, access to specialty care, and significant investment in research and development.
Notable therapeutic advancements, such as the widespread use of GLP 2 analogs like teduglutide, and active clinical trials for next-generation treatments, further cement North America’s leadership in the SBS market. With over 70% global market share as of 2023, the region is well-positioned to maintain its dominance in the coming years.
Asia-Pacific is growing at the fastest pace in the short bowel syndrome market, holding 19.6% of the market share
Asia-Pacific is expected to emerge as the fastest-growing region in the short bowel syndrome (SBS) market, propelled by rising healthcare investments, growing awareness of rare gastrointestinal disorders, and improving access to specialized care. Countries such as China, India, Japan, and South Korea are witnessing a steady increase in SBS-related hospitalizations, primarily due to higher survival rates of premature infants and rising cases of conditions like Crohn’s disease and bowel ischemia.
The Asia-Pacific region's evolving healthcare landscape and rising demand for advanced gastrointestinal treatments position it as a key area of opportunity in the global SBS market.
Short Bowel Syndrome Market Competitive Landscape
Top companies in the short bowel syndrome market include Takeda Pharmaceutical Company Limited, OxThera, and Nutricia North America, among others.
Short Bowel Syndrome Market, Key Developments
In 2023, the global short bowel syndrome market was valued at US$ 1.39 Billion, and the market size reached US$ 1.64 Billion in 2024 and is expected to reach US$ 7.93 Billion by 2033, growing at a CAGR of 19.3% during the forecast period 2025-2033.
Short Bowel Syndrome Market Overview
The global short bowel syndrome (SBS) market is undergoing rapid evolution, driven by the growing incidence of gastrointestinal surgeries, particularly in neonates, along with increased adoption of advanced therapies such as GLP-2 analogs, including teduglutide. Key market drivers include rising prevalence of SBS due to conditions like Crohn’s disease and necrotizing enterocolitis, the clinical success of absorption-enhancing drugs that reduce reliance on parenteral nutrition, and improving access to care in emerging markets.
North America dominates the market due to high diagnosis rates, established reimbursement frameworks, and early drug approvals. Meanwhile, Asia-Pacific is the fastest-growing region, fueled by rising awareness, expanding pediatric surgical capabilities, and strategic entry by global pharmaceutical players.
Emerging opportunities lie in the development of biosimilars to reduce treatment costs, digital platforms for individualized nutrition management, and a robust pipeline of long-acting GLP-2 analogs and regenerative therapies that address long-term intestinal failure. These trends position the SBS market as a high-value niche with substantial room for targeted innovation and regional expansion.
Short Bowel Syndrome Market Dynamics: Drivers & Restraints
Drivers:
Rising prevalence of SBS & related GI disorders is significantly driving the short bowel syndrome market growth
The rising prevalence of short bowel syndrome (SBS), driven by increasing rates of gastrointestinal surgeries, Crohn’s disease, and necrotizing enterocolitis, especially among neonates and older adults, is a key growth driver for the SBS market. As more patients are diagnosed with SBS and require long-term nutritional and therapeutic support, demand for specialized treatments such as GLP-2 analogs and parenteral nutrition continues to rise.
This expanding patient population not only creates a larger commercial opportunity for pharmaceutical companies but also accelerates investment in drug development, diagnostic tools, and supportive care infrastructure, collectively propelling market growth.
Advancements in therapeutics are expected to boost the Short Bowel Syndrome market growth
Advancements in therapeutics are playing a pivotal role in driving growth in the Short Bowel Syndrome (SBS) market by offering more effective and convenient treatment options that reduce reliance on parenteral nutrition. A notable example is Apraglutide, a long-lasting GLP 2 analogue developed by Ironwood/VectivBio, which recently demonstrated statistically significant reductions in weekly parenteral support in a Phase III trial.
Another notable development is Glepaglutide from Zealand Pharma, an investigational GLP 2 analog in an autoinjector format, which earned FDA orphan drug designation and showed strong phase III results, though a Complete Response Letter in December 2024 prompted plans for an additional confirmatory trial. Collectively, such developments are fueling investment and adoption in the SBS market, creating sustained growth momentum.
Restraint:
The high cost of treatment and nutritional support are hampering the growth of the Short Bowel Syndrome market
The high cost of treatment and nutritional support is a significant barrier to the growth of the Short Bowel Syndrome (SBS) market, particularly in low- and middle-income regions. Managing SBS often requires lifelong dependence on parenteral nutrition (PN), specialized medical care, and advanced pharmacological therapies such as GLP 2 analogs (e.g., teduglutide).
For instance, teduglutide therapy can exceed $300,000 annually per patient in the U.S., while long-term PN can cost tens of thousands of dollars each year, excluding the additional burden of hospitalizations, catheter-related infections, and liver complications.
Opportunity:
Emergence of novel therapies is expected to create a lucrative opportunity for the growth of the short bowel syndrome market
Focusing on immuno-oncology and precision medicine is expected to create lucrative opportunities for the short bowel syndrome market by enabling the development of highly targeted, effective treatments tailored to individual patients. thymic tumors often present unique molecular and immune characteristics, making them suitable candidates for precision-based approaches. advances in genomic profiling, biomarker identification, and next-generation sequencing are allowing researchers to better understand the biology of short bowel syndrome, leading to the creation of personalized therapies that improve treatment response and reduce side effects.
Short Bowel Syndrome Market, Segment Analysis
The global short bowel syndrome market is segmented based on drug class, Route of Administration, distribution channel, and region.
The GLP-2 analogs from the drug class segment are expected to hold 31.6% of the market share in 2024 in the short bowel syndrome market
The GLP-2 analogs segment is expected to dominate the short bowel syndrome (SBS) drug market due to its targeted mechanism of action, proven clinical efficacy, and increasing regulatory approvals. GLP-2 (glucagon-like peptide-2) analogs enhance intestinal absorption by promoting mucosal growth and improving fluid and nutrient uptake, reducing the dependence on parenteral nutrition.
Teduglutide (marketed as Gattex in the U.S. and Revestive in Europe), the first GLP-2 analog approved by the FDA and EMA, has shown significant improvements in patients' nutritional autonomy and quality of life, driving strong adoption. Moreover, the segment is gaining momentum from a robust pipeline of next-generation GLP-2 analogs. For instance, Apraglutide by Ironwood Pharmaceuticals (formerly VectivBio) demonstrated positive Phase III results in 2024, showing a substantial reduction in weekly parenteral support volumes.
Similarly, Glepaglutide, developed by Zealand Pharma, is under regulatory review following Phase III trials, with additional studies planned after receiving a Complete Response Letter from the FDA in late 2024. These agents offer longer half-lives and more convenient dosing schedules, which are likely to further increase patient adherence and physician preference. As these advanced GLP-2 analogs enter the market, this drug class is well-positioned to remain the cornerstone of SBS pharmacological therapy.
Short Bowel Syndrome Market, Geographical Analysis
North America is expected to dominate the global short bowel syndrome market with a 40.3% share in 2024
North America is expected to dominate the global short bowel syndrome (SBS) market, largely due to its high disease burden, advanced healthcare infrastructure, and early adoption of innovative treatments. The region, particularly the United States, accounts for the majority of SBS cases globally. Byrne et al. estimated that around 10,000 to 20,000 patients in the United States receive home-based total parenteral nutrition (TPN) for short bowel syndrome (SBS). Patients are dependent on long-term home parenteral nutrition. The rising incidence of conditions leading to SBS alongside improved survival rates among preterm infants has expanded the patient population. Moreover, the region benefits from strong reimbursement frameworks, access to specialty care, and significant investment in research and development.
Notable therapeutic advancements, such as the widespread use of GLP 2 analogs like teduglutide, and active clinical trials for next-generation treatments, further cement North America’s leadership in the SBS market. With over 70% global market share as of 2023, the region is well-positioned to maintain its dominance in the coming years.
Asia-Pacific is growing at the fastest pace in the short bowel syndrome market, holding 19.6% of the market share
Asia-Pacific is expected to emerge as the fastest-growing region in the short bowel syndrome (SBS) market, propelled by rising healthcare investments, growing awareness of rare gastrointestinal disorders, and improving access to specialized care. Countries such as China, India, Japan, and South Korea are witnessing a steady increase in SBS-related hospitalizations, primarily due to higher survival rates of premature infants and rising cases of conditions like Crohn’s disease and bowel ischemia.
The Asia-Pacific region's evolving healthcare landscape and rising demand for advanced gastrointestinal treatments position it as a key area of opportunity in the global SBS market.
Short Bowel Syndrome Market Competitive Landscape
Top companies in the short bowel syndrome market include Takeda Pharmaceutical Company Limited, OxThera, and Nutricia North America, among others.
Short Bowel Syndrome Market, Key Developments
- In April 2025, Ironwood Pharmaceuticals announced that the FDA had requested a confirmatory Phase 3 trial for apraglutide in patients with short bowel syndrome with intestinal failure (SBS-IF) reliant on parenteral support. While continuing development, the company has engaged Goldman Sachs to explore strategic options aimed at maximizing shareholder value.
- In January 2025, Ironwood Pharmaceuticals announced a renewed strategic focus on advancing apraglutide for short bowel syndrome (SBS) patients dependent on parenteral support. As part of this shift, the company will reduce its workforce by about 50% to better align resources and support long-term growth.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
3.2. Snippet by Drug Class
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of SBS & Related GI Disorders
4.1.1.2. Advancements in Therapeutics
4.1.1.3. Supportive Regulatory framework
4.1.2. Restraints
4.1.2.1. High Cost of Treatment and Nutritional Support
4.1.2.2. Limited Awareness in Developing Regions
4.1.2.3. Complications from Parenteral Nutrition
4.1.3. Opportunity
4.1.3.1. Emergence of Novel Therapies
4.1.3.2. Expansion in Emerging Markets
4.1.4. Impact Analysis
5. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
5.1. Market Leaders and Pioneers
5.1.1. Emerging Pioneers and Prominent Players
5.1.2. Established Leaders with the Largest Marketing Brand
5.1.3. Market Leaders with Established Products
5.2. Latest Developments and Breakthroughs
5.3. Regulatory and Reimbursement Landscape
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. South America
5.3.5. Middle East & Africa
5.4. Porter’s Five Forces Analysis
5.5. Supply Chain Analysis
5.6. Pipeline Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
5.9. Unmet Needs and Gaps
5.10. Recommended Strategies for Market Entry and Expansion
5.11. Pricing Analysis and Price Dynamics
6. SHORT BOWEL SYNDROME MARKET, BY DRUG CLASS
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
6.1.2. Market Attractiveness Index, By Drug Class
6.2. GLP-2 analogs*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Growth Hormones
6.4. Glutamine
6.5. Others
7. SHORT BOWEL SYNDROME MARKET, BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Medications & Supplements*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Enteral
7.4. Parenteral
7.5. Others
8. SHORT BOWEL SYNDROME MARKET, BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Others
9. SHORT BOWEL SYNDROME MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
10. INTRODUCTION
10.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.1. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. MARKET SIZE ANALYSIS AND Y-O-Y GROWTH ANALYSIS (%), BY COUNTRY
11.1. U.S.
11.1.1. Canada
11.1.1.1. Mexico
11.2. Europe
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.6.1. Germany
11.2.6.2. UK
11.2.6.3. France
11.2.6.4. Spain
11.2.6.5. Italy
11.2.6.6. Rest of Europe
11.3. Asia-Pacific
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.6.1. China
11.3.6.2. India
11.3.6.3. Japan
11.3.6.4. South Korea
11.3.6.5. Rest of Asia-Pacific
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.6.1. Brazil
11.4.6.2. Argentina
11.4.6.3. Rest of South America
11.5. Middle East and Africa
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
13. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
13.1. Market Share Analysis and Positioning Matrix
13.2. Strategic Partnerships, Mergers & Acquisitions
13.3. Key Developments in Product Portfolios and Innovations
13.4. Company Benchmarking
13.5. Key Players
14. COMPANY PROFILES
14.1. Takeda Pharmaceutical Company Limited*
14.1.1. Company Overview
14.1.2. Product Portfolio
14.1.2.1. Product Description
14.1.2.2. Product Key Performance Indicators (KPIs)
14.1.3. Financial Overview
14.1.4. Company Revenue
14.1.4.1. Geographical Revenue Shares
14.1.4.2. Revenue Forecasts
14.1.5. Key Developments
14.1.5.1. Mergers & Acquisitions
14.1.5.2. Key Product Development Activities
14.1.5.3. Regulatory Approvals, etc.
14.1.5.4. SWOT Analysis
14.2. OxThera
14.3. Nutricia North America
15. EMERGING PLAYERS
15.1. Pfizer Inc
15.2. ZEALAND PHARMA
15.3. Ironwood (VectivBio AG)(LIST NOT EXHAUSTIVE )
16. ASSUMPTIONS AND RESEARCH METHODOLOGY
16.1. Data Collection Methods
16.2. Data Triangulation
16.3. Forecasting Techniques
16.4. Data Verification and Validation
17. APPENDIX
17.1. About Us and Services
17.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
3.2. Snippet by Drug Class
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of SBS & Related GI Disorders
4.1.1.2. Advancements in Therapeutics
4.1.1.3. Supportive Regulatory framework
4.1.2. Restraints
4.1.2.1. High Cost of Treatment and Nutritional Support
4.1.2.2. Limited Awareness in Developing Regions
4.1.2.3. Complications from Parenteral Nutrition
4.1.3. Opportunity
4.1.3.1. Emergence of Novel Therapies
4.1.3.2. Expansion in Emerging Markets
4.1.4. Impact Analysis
5. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
5.1. Market Leaders and Pioneers
5.1.1. Emerging Pioneers and Prominent Players
5.1.2. Established Leaders with the Largest Marketing Brand
5.1.3. Market Leaders with Established Products
5.2. Latest Developments and Breakthroughs
5.3. Regulatory and Reimbursement Landscape
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. South America
5.3.5. Middle East & Africa
5.4. Porter’s Five Forces Analysis
5.5. Supply Chain Analysis
5.6. Pipeline Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
5.9. Unmet Needs and Gaps
5.10. Recommended Strategies for Market Entry and Expansion
5.11. Pricing Analysis and Price Dynamics
6. SHORT BOWEL SYNDROME MARKET, BY DRUG CLASS
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
6.1.2. Market Attractiveness Index, By Drug Class
6.2. GLP-2 analogs*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Growth Hormones
6.4. Glutamine
6.5. Others
7. SHORT BOWEL SYNDROME MARKET, BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Medications & Supplements*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Enteral
7.4. Parenteral
7.5. Others
8. SHORT BOWEL SYNDROME MARKET, BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Others
9. SHORT BOWEL SYNDROME MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
10. INTRODUCTION
10.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.1. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. MARKET SIZE ANALYSIS AND Y-O-Y GROWTH ANALYSIS (%), BY COUNTRY
11.1. U.S.
11.1.1. Canada
11.1.1.1. Mexico
11.2. Europe
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.6.1. Germany
11.2.6.2. UK
11.2.6.3. France
11.2.6.4. Spain
11.2.6.5. Italy
11.2.6.6. Rest of Europe
11.3. Asia-Pacific
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.6.1. China
11.3.6.2. India
11.3.6.3. Japan
11.3.6.4. South Korea
11.3.6.5. Rest of Asia-Pacific
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.6.1. Brazil
11.4.6.2. Argentina
11.4.6.3. Rest of South America
11.5. Middle East and Africa
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
13. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
13.1. Market Share Analysis and Positioning Matrix
13.2. Strategic Partnerships, Mergers & Acquisitions
13.3. Key Developments in Product Portfolios and Innovations
13.4. Company Benchmarking
13.5. Key Players
14. COMPANY PROFILES
14.1. Takeda Pharmaceutical Company Limited*
14.1.1. Company Overview
14.1.2. Product Portfolio
14.1.2.1. Product Description
14.1.2.2. Product Key Performance Indicators (KPIs)
14.1.3. Financial Overview
14.1.4. Company Revenue
14.1.4.1. Geographical Revenue Shares
14.1.4.2. Revenue Forecasts
14.1.5. Key Developments
14.1.5.1. Mergers & Acquisitions
14.1.5.2. Key Product Development Activities
14.1.5.3. Regulatory Approvals, etc.
14.1.5.4. SWOT Analysis
14.2. OxThera
14.3. Nutricia North America
15. EMERGING PLAYERS
15.1. Pfizer Inc
15.2. ZEALAND PHARMA
15.3. Ironwood (VectivBio AG)(LIST NOT EXHAUSTIVE )
16. ASSUMPTIONS AND RESEARCH METHODOLOGY
16.1. Data Collection Methods
16.2. Data Triangulation
16.3. Forecasting Techniques
16.4. Data Verification and Validation
17. APPENDIX
17.1. About Us and Services
17.2. Contact Us
LIST OF TABLES
Table 1 Global Short Bowel Syndrome Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Short Bowel Syndrome Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Short Bowel Syndrome Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Short Bowel Syndrome Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Short Bowel Syndrome Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Short Bowel Syndrome Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 7 Global Short Bowel Syndrome Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Short Bowel Syndrome Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 9 Global Short Bowel Syndrome Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Short Bowel Syndrome Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 11 Global Short Bowel Syndrome Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Short Bowel Syndrome Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Short Bowel Syndrome Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 14 North America Short Bowel Syndrome Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 15 North America Short Bowel Syndrome Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 16 North America Short Bowel Syndrome Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Asia-Pacific Short Bowel Syndrome Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 18 Asia-Pacific Short Bowel Syndrome Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 19 Asia-Pacific Short Bowel Syndrome Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 Asia-Pacific Short Bowel Syndrome Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Short Bowel Syndrome Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 22 Europe Short Bowel Syndrome Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 23 Europe Short Bowel Syndrome Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 24 Europe Short Bowel Syndrome Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Short Bowel Syndrome Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 26 South America Short Bowel Syndrome Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 27 South America Short Bowel Syndrome Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 28 South America Short Bowel Syndrome Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Short Bowel Syndrome Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Short Bowel Syndrome Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Short Bowel Syndrome Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Short Bowel Syndrome Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Takeda Pharmaceutical Company Limited: Overview
Table 34 Takeda Pharmaceutical Company Limited: Product Portfolio
Table 35 Takeda Pharmaceutical Company Limited: Key Developments
Table 36 OxThera: Overview
Table 37 OxThera: Product Portfolio
Table 38 OxThera: Key Developments
Table 39 Nutricia North America: Overview
Table 40 Nutricia North America: Product Portfolio
Table 41 Nutricia North America: Key Developments
Table 1 Global Short Bowel Syndrome Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Short Bowel Syndrome Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Short Bowel Syndrome Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Short Bowel Syndrome Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Short Bowel Syndrome Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Short Bowel Syndrome Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 7 Global Short Bowel Syndrome Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Short Bowel Syndrome Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 9 Global Short Bowel Syndrome Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Short Bowel Syndrome Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 11 Global Short Bowel Syndrome Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Short Bowel Syndrome Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Short Bowel Syndrome Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 14 North America Short Bowel Syndrome Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 15 North America Short Bowel Syndrome Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 16 North America Short Bowel Syndrome Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Asia-Pacific Short Bowel Syndrome Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 18 Asia-Pacific Short Bowel Syndrome Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 19 Asia-Pacific Short Bowel Syndrome Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 Asia-Pacific Short Bowel Syndrome Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Short Bowel Syndrome Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 22 Europe Short Bowel Syndrome Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 23 Europe Short Bowel Syndrome Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 24 Europe Short Bowel Syndrome Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Short Bowel Syndrome Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 26 South America Short Bowel Syndrome Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 27 South America Short Bowel Syndrome Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 28 South America Short Bowel Syndrome Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Short Bowel Syndrome Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Short Bowel Syndrome Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Short Bowel Syndrome Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Short Bowel Syndrome Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Takeda Pharmaceutical Company Limited: Overview
Table 34 Takeda Pharmaceutical Company Limited: Product Portfolio
Table 35 Takeda Pharmaceutical Company Limited: Key Developments
Table 36 OxThera: Overview
Table 37 OxThera: Product Portfolio
Table 38 OxThera: Key Developments
Table 39 Nutricia North America: Overview
Table 40 Nutricia North America: Product Portfolio
Table 41 Nutricia North America: Key Developments
LIST OF FIGURES
Figure 1 Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Short Bowel Syndrome Market Share, By Drug Class, 2024 & 2033 (%)
Figure 3 Global Short Bowel Syndrome Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 4 Global Short Bowel Syndrome Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 5 Global Short Bowel Syndrome Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Short Bowel Syndrome Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)
Figure 7 GLP-2 analogs Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 8 Growth Hormones Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 9 Glutamine Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 10 Others Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 11 Global Short Bowel Syndrome Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 12 Medications & Supplements Route of Administration in Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 13 Enteral Route of Administration in Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 14 Parenteral Route of Administration in Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 15 Others Route of Administration in Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Short Bowel Syndrome Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 17 Hospital Pharmacies Distribution Channel in Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 18 Retail Pharmacies Distribution Channel in Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 19 Others Distribution Channel in Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Short Bowel Syndrome Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 21 North America Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 22 North America Short Bowel Syndrome Market Share, By Drug Class, 2024 & 2033 (%)
Figure 23 North America Short Bowel Syndrome Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 24 North America Short Bowel Syndrome Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 25 North America Short Bowel Syndrome Market Share, By Country, 2024 & 2033 (%)
Figure 26 Asia-Pacific Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 27 Asia-Pacific Short Bowel Syndrome Market Share, By Drug Class, 2024 & 2033 (%)
Figure 28 Asia-Pacific Short Bowel Syndrome Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 29 Asia-Pacific Short Bowel Syndrome Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 30 Asia-Pacific Short Bowel Syndrome Market Share, By Country, 2024 & 2033 (%)
Figure 31 Europe Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 32 Europe Short Bowel Syndrome Market Share, By Drug Class, 2024 & 2033 (%)
Figure 33 Europe Short Bowel Syndrome Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 34 Europe Short Bowel Syndrome Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 35 Europe Short Bowel Syndrome Market Share, By Country, 2024 & 2033 (%)
Figure 36 South America Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 37 South America Short Bowel Syndrome Market Share, By Drug Class, 2024 & 2033 (%)
Figure 38 South America Short Bowel Syndrome Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 39 South America Short Bowel Syndrome Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 40 South America Short Bowel Syndrome Market Share, By Country, 2024 & 2033 (%)
Figure 41 Middle East and Africa Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 42 Middle East and Africa Short Bowel Syndrome Market Share, By Drug Class, 2024 & 2033 (%)
Figure 43 Middle East and Africa Short Bowel Syndrome Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 44 Middle East and Africa Short Bowel Syndrome Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 45 Takeda Pharmaceutical Company Limited: Financials
Figure 46 OxThera: Financials
Figure 47 Nutricia North America: Financials
Figure 1 Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Short Bowel Syndrome Market Share, By Drug Class, 2024 & 2033 (%)
Figure 3 Global Short Bowel Syndrome Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 4 Global Short Bowel Syndrome Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 5 Global Short Bowel Syndrome Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Short Bowel Syndrome Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)
Figure 7 GLP-2 analogs Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 8 Growth Hormones Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 9 Glutamine Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 10 Others Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 11 Global Short Bowel Syndrome Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 12 Medications & Supplements Route of Administration in Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 13 Enteral Route of Administration in Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 14 Parenteral Route of Administration in Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 15 Others Route of Administration in Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Short Bowel Syndrome Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 17 Hospital Pharmacies Distribution Channel in Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 18 Retail Pharmacies Distribution Channel in Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 19 Others Distribution Channel in Global Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Short Bowel Syndrome Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 21 North America Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 22 North America Short Bowel Syndrome Market Share, By Drug Class, 2024 & 2033 (%)
Figure 23 North America Short Bowel Syndrome Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 24 North America Short Bowel Syndrome Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 25 North America Short Bowel Syndrome Market Share, By Country, 2024 & 2033 (%)
Figure 26 Asia-Pacific Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 27 Asia-Pacific Short Bowel Syndrome Market Share, By Drug Class, 2024 & 2033 (%)
Figure 28 Asia-Pacific Short Bowel Syndrome Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 29 Asia-Pacific Short Bowel Syndrome Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 30 Asia-Pacific Short Bowel Syndrome Market Share, By Country, 2024 & 2033 (%)
Figure 31 Europe Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 32 Europe Short Bowel Syndrome Market Share, By Drug Class, 2024 & 2033 (%)
Figure 33 Europe Short Bowel Syndrome Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 34 Europe Short Bowel Syndrome Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 35 Europe Short Bowel Syndrome Market Share, By Country, 2024 & 2033 (%)
Figure 36 South America Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 37 South America Short Bowel Syndrome Market Share, By Drug Class, 2024 & 2033 (%)
Figure 38 South America Short Bowel Syndrome Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 39 South America Short Bowel Syndrome Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 40 South America Short Bowel Syndrome Market Share, By Country, 2024 & 2033 (%)
Figure 41 Middle East and Africa Short Bowel Syndrome Market Value, 2022-2033 (US$ Billion)
Figure 42 Middle East and Africa Short Bowel Syndrome Market Share, By Drug Class, 2024 & 2033 (%)
Figure 43 Middle East and Africa Short Bowel Syndrome Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 44 Middle East and Africa Short Bowel Syndrome Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 45 Takeda Pharmaceutical Company Limited: Financials
Figure 46 OxThera: Financials
Figure 47 Nutricia North America: Financials
